The new report* states that the prostate cancer market has historically been dominated by chemotherapies and hormone therapies, with major players including AstraZeneca, which market the hormone therapies Zoladex (goserelin acetate) and Casodex (bicalutamide)
the popular chemotherapies Taxotere (docetaxel) and Jevtana (cabazitaxel)
Hormone therapies will continue to be a mainstay of prostate cancer treatment, but the role of chemotherapies will be reduced as targeted therapies like Johnson & Johnson’s (J&J’s)
mCRPC patients characterize the disease population with the greatest unmet need of all prostate cancer patients. While patients with early stage prostate cancer can often be cured with surgery and radiation therapy, the cancer suffered by mCRPC patients is incurable, and they often suffer from painful symptoms related to bone metastases.
For Sample Pages, please click or add the below link to your browser:
However, recent market entrants J&J’s Zytiga and Medivation/Astellas’
Following the expected European launch of Xtandi in 2013, Zytiga and Xtandi will globally become the favored mCRPC treatments due to their oral route of administration and good level of tolerance by patients. J&J, Medivation, and Astellas initially sought regulatory approval for their drugs in mCRPC patients who are refractory to chemotherapy drug docetaxel, the current gold standard medication. Ultimately, they will expand their brands to the more lucrative chemotherapy-
GlobalData predict that Zytiga and Xtandi will dominate the mCRPC space, expecting peak Zytiga sales of US$1.7 billion in 2018, and Xtandi sales increasing to US$2.05 billion by 2022. However, increasing pressures to prove cost-effectiveness could restrain growth in the prostate cancer market, particularly in
Europe, as reimbursement hurdles and price cuts will limit the premium pricing and uptake of new drugs. Alpharadin and other promising pipeline drugs that will launch over the next decade are also anticipated to have a difficult time capturing significant market share, as the market becomes crowded with competitors.
The anticipated success of Zytiga and Xtandi, as well as the launch of a wealth of first-in-class pipeline products, will drive sales of prostate cancer therapeutics to increase from an estimated US$3.8 billion in 2012 to US$7.9 billion by 2022 in the US, the UK, France, Germany, Spain, Italy, Japan, Australia, and Canada.
This report provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifying and analyzing key trends shaping the market. It analyses treatment usage patterns and provides insights into the competitive landscape and emerging players. The report quantifies the unmet need in the global market, and individual markets such as the US and the top five countries in Europe.
For further details, please click or add the below link to your browser:
Visit our report store:
For more details contact:pressreleases@
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782